PBGENE PCSK9
Alternative Names: PBGENE-PCSK9Latest Information Update: 28 Mar 2025
At a glance
- Originator Precision Biosciences
- Class Antihyperlipidaemics; Endodeoxyribonucleases
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperlipoproteinaemia type IIa
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Hyperlipoproteinaemia-type-IIa in USA (IV)
- 28 Feb 2023 Precision BioSciences receives a notice of allowance from the US Patent and Trademark Office (USPTO) for US Patent Application No. 16/606,856, titled “Engineered meganucleases specific for recognition sequences in the PCSK9 gene
- 31 Jan 2023 Precision BioSciences terminates its licence for PBGENE PCSK9 with iECURE